BHVN
Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload
Article Summary
HOLD- Biohaven Ltd. (NYSE: BHVN) announced that new clinical data on its novel FGFR3-directed antibody-drug conjugate using a novel TopoIx payload will be presented at the European Society for Medical Oncology Congress 2026, with Biohaven entering into a clinical supply agreement with Regeneron Pharmaceuticals Inc. to evaluate the combination of BV-1530 and cemiplimab (Libtayo) in patients with solid tumors based on emerging monotherapy clinical data and preclinical data demonstrating synergistic activity between the drug and immune therapy.
- Early Phase 1 data from May 27 2026 showed early signs of antitumor activity across both FGFR-altered and wild-typeoverexpressing tumors, with no dose-limiting toxicities and no FGFR inhibitor-class toxicities such as hyperphosphatemia, nail disorders, stomatitis, or retinopathy.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 0.0% | 25% | 20.0 ptsMinimal (0.0%) - Very weak |
| EPS Growth Next 5Y ? | 33.4% | 25% | 90.0 ptsExcellent (33.4%) - Strong outlook |
| Target Price Upside ? | 49.0% | 20% | 95.0 ptsHuge Upside (49.0%) - Target: $22.40 vs Current: $15.03 |
| Gross Margin % ? | — | 15% | 40.0 ptsNo Gross Margin Data |
| Drawdown from 52-Wk High ? | -19.0% | 15% | 40.0 ptsMild Pullback (-19.0%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About BHVN
- Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide.
- It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
- The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors.
- In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus.
- The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022.
- Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.